Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mesa Laboratories SEC filings document the company's life sciences tools and critical quality control business, its Nasdaq-listed common stock and formal disclosures around operating results, governance and capital structure. Form 8-K reports furnish quarterly financial releases, record annual meeting voting outcomes and report executive succession, director changes and related compensation arrangements.
Other filings and exhibits describe the company's credit facility borrowings, convertible note settlement funding, independent auditor ratification, board committee structure and proxy compensation disclosures. These records frame Mesa's disclosure obligations across its four operating divisions and its financing, shareholder-vote and leadership-transition matters.
Mesa Laboratories director Shiraz Shabanali Ladiwala reported an open-market purchase of 3,500 shares of Mesa Laboratories common stock at $72.23 per share. This buy on March 10, 2026 increased his directly held position to 8,523 shares, signaling a larger personal stake in the company.
Mesa Laboratories director Mark Christopher Capone bought additional company stock in an open-market transaction. He purchased 1,301 shares of Common Stock at a price of $76.35 per share. After this purchase, he directly owns 3,429 shares of Mesa Laboratories Common Stock.
Mesa Laboratories director R. Tony Tripeny bought shares of the company in the open market. He purchased 1,315 shares of Mesa Laboratories common stock at a price of $76.00 per share. After this transaction, his direct ownership increased to 5,398 common shares.
Mesa Laboratories is making a planned leadership change. Gary Owens will step down as President and CEO around April 12–13, 2026, with the company stating his departure is not due to any disagreement over operations, policies, or practices.
The Board has appointed Dr. Siddhartha Kadia as the new President and CEO and as a director, effective April 13, 2026. Under his employment agreement, he will receive an annual base salary of $850,000, a target annual bonus equal to at least 100% of salary, and initial equity awards of RSUs valued at $3.0 million and PSUs with a target value of $3.0 million, subject to multi‑year vesting and performance conditions.
Mesa Laboratories delivered modest top-line growth with stronger profits for the nine months ended December 31, 2025. Revenue rose to $185.4 million from $178.8 million, while net income more than doubled to $10.8 million, lifting diluted EPS to $1.95 from $0.94.
Growth came mainly from Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions, while Clinical Genomics declined due to weaker demand in China. Gross margin stayed solid at 62.6%, and operating income improved to $15.8 million.
The company refinanced its 1.375% convertible notes, settling the $97.5 million principal at maturity using its credit facility, which now includes a $68.4 million term loan and $98.3 million drawn on the revolver. Cash was $29.0 million, with operating cash flow of $28.9 million and continued quarterly dividends of $0.16 per share. Management highlights ongoing macro headwinds in China and notes that the Clinical Genomics unit remains more sensitive to potential future goodwill impairment.
Mesa Laboratories, Inc. filed a current report to let investors know it has released financial results. On February 3, 2026, the company issued a press release covering its performance for the three and nine months ended December 31, 2025.
The press release is included as Exhibit 99.1 and is provided as supplemental information. The company specifies that this earnings information is being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities offerings.
Mesa Laboratories Inc. director reports a gift of company stock. A Form 4 filing shows that on 12/02/2025, the reporting director disposed of 2,000 shares of Mesa Laboratories common stock in a transaction coded "G," which indicates a gift, at a reported price of $0.
Following this transaction, the director beneficially owns 25,282 shares directly and 44,780 shares indirectly through a spousal lifetime access trust. The filing notes that the indirectly held shares are owned by a trust for a spouse’s benefit, which the director reports as indirect beneficial ownership.
Mesa Laboratories (MLAB) reported Q2 FY2026 results with revenues of $60.7 million, up 5% year over year, and gross profit of $37.3 million (61.5% margin). Operating income rose to $4.7 million, while net income was $2.5 million and diluted EPS was $0.45, reflecting higher interest and lower non‑operating gains versus last year.
Growth was led by Biopharmaceutical Development (revenue $13.9 million, +17.3%) and Calibration Solutions (revenue $13.6 million, +10.7%). Sterilization and Disinfection Control was flat, and Clinical Genomics declined modestly as China revenue fell to $5.3 million from $7.4 million. For the first half, revenue reached $120.3 million (+3.7%) and diluted EPS was $1.30.
The company retired its 1.375% convertible notes at maturity on August 15, 2025 using its revolver and cash; no notes remain outstanding. The revolver balance was $106.0 million at quarter‑end, and an October amendment lowered the spread, reducing the borrowing rate from 7.1% to 6.7%. Cash was $20.4 million. Mesa initiated cost actions expected to reduce annualized costs by about $3.2 million, with $0.9 million to be reinvested, implying $2.3 million net savings starting in Q3; approximately $0.85 million in severance was incurred.
Mesa Laboratories (MLAB) announced it issued a press release covering results for the three and six months ended September 30, 2025. The company furnished the press release as Exhibit 99.1 to this Form 8‑K.
The information provided with the press release is being furnished, not filed, which means it is not subject to Section 18 liabilities and is not incorporated by reference into Securities Act filings. The filing lists MLAB common stock on The Nasdaq Stock Market LLC.
Mesa Laboratories (MLAB) reported an insider equity change: the President and CEO acquired 11,558 shares of common stock on 10/27/2025 via a transaction coded M, reflecting settlement of performance share units at a reported price of $0.
Following this transaction, the officer directly holds 64,135 shares. The shares relate to performance share units granted on 10/28/2021 as a special award intended to encourage continued performance and long-term retention, vesting one-third on 10/27/2024 and on each of the next two anniversary dates.